Our proprietary technology, CLoNeT™, is a revolutionary antibiotic stewardship tool. CLoNeT™ is a rapid (<45 min) diagnostic test that assigns proprietary ‘barcodes’ to infecting bacteria by identifying a few fingerprint regions of bacterial DNA. Our barcoding approach has broad applicability to diverse pathogens. CLoNeT™ holds the potential to improve clinical outcomes for multiple infectious diseases that are plagued with increasing antibiotic resistance.
First-generation CLoNeT™ tests target urinary tract infections, which are at the forefront of the drug resistance crisis. A partnership with GroupHealth Research Institute in Seattle, WA has permitted early stage clinical observational trials of first-generation CLoNeT™ in the urgent care setting.
These urgent-care clinical trials show that our first generation product yields results in 25-40 minutes, and reduces the rate of antibiotic prescription errors for UTIs from 1 in 4 to less than 3%.
We have calculated that CLoNeT™ 2.0 will reduce error rates well below 3%. IDG’s R&D efforts have demonstrated that our proprietary ‘barcoding’ method can also be applied to other infectious pathogens.
The next-generation product, CLoNeT™2.0, is currently under development. CLoNeT™R&D pipelines are also active for other infectious indications.
At a time of rampant antibiotic resistance, our products promote the use of appropriate antibiotics, reduce artificial pressures on microbes to develop resistance, and contain the spread of resistant organisms.
